A research scientist at work in the laboratory reproduced with kind permission of Oxfordshire-based oncology therapeutics company Chroma Therapeutics

*Submit your email address to receive conference udpates

Company Showcase featuring the Most Promising Emerging Companies and Clinical Stage Developments (15-16th April).

Companies presenting at BioTrinity 2008 have 33 compounds in pre-clinical develompent and 25 in clinical development excluding big pharma participants. Do attend the OBN BioCluster Report launch for access to the most complete analysis yet of the Oxford BioCluster.

The BioTrinity 2008 - Oxford Company Showcase is a unique opportunity to take in showcase presentations from the best companies from the UK's most successful biotech supercluster and partner with them. Delegates may also be interested in the spin-out and licensing opportunities on offer from Isis Innovation and others in the Technology Showcase
Tuesday, 15th April 2008
13.00	Drug Discovery and Development (Therapeutics)
	11.45 (OSI) Prosidion - Anker Lundemose, Executive VP, OSI Pharmaceuticals, Inc. & President of OSI Prosidion "A UK Contribution to the Success of a NASDAQ-listed US Biotech"
	13.00 Chroma Therapeutics - Scott Cuthill, Business Development Manager, Chroma Therapeutics: A Snapshot of the Oncology Pipeline
	13.15 PhynovaDr John Efthimiou, Chief Medical Officer, Botanical Drugs: A New Pharmaceutical Paradigm
	13.30 BioVexColin Love, SVP Product Development, OncoVEX - To Phase III and Beyond
	13.45 Celleron Therapeutics Nick La Thangue, Founding Director, Celleron Therapeutics: Targeted Cancer Medicines
	14.00 Hybrid Systems Kerry Fisher, CEO, Polymer coated ‘Stealth’ viruses for vaccine and therapeutic applications
	14.15 Spirogen Chris Martin, CEO Clinical Development of a Novel Class of Oncology Drug
	15:00 Oxford Genome Sciences -Christian Rohlff, CEO, An Integrated Approach to the Development of Novel Antibody Therapeutics in Cancer
15.15	Drug Delivery
	15:15 Glide Pharma -Charles Potter, CEO, Glide SDITM - The injection of drugs and vaccines in a solid dosage form
	15.30 Biocompatibles Donald Coppen, Partnering & Licensing Manager, CellBeads: Using stem cells in drug delivery - a novel clinical-stage, long-term delivery product
15.45	Drug Discovery and Development
	15.45 Pharmidex Pharmaceutical Services Alistair Dixon, Business Development Manager, Assessment and delivery of compounds across the blood-brain barrier
	16.00 Epistem Matthew Walls, CEO
16.00	OBN BioCluster Report 2008 Launch and Reception

Wednesday, 16th April 2008 (16 Speaking Slots)
10.15	Drug Discovery and Development - CNS Therapeutic Focus
	10.15 Evotec -Mark Ashton, EVP Business Development, Evotec: the partner of choice
	11.00 Summit plcSteven Lee, CEO, Zebrafish models in drug discovery
	11.15 Capsant NeurotechnologiesProf Lars Sundstrom, Director, Chief Scientific Officer, Capsant; Developing high throughput human tissue testing
11.30	Drug Discovery and Development - Therapeutic Focus
	11.30 ChemoCentryx - Thomas Schall, President and CEO, Novel drug discovery platform yields new drugs for chronic inflammatory disorders such as Crohn's disease
	11.45 Syntaxin - Phil Boyd, CFO, Engineering and developing novel drugs controlling cell secretion.
12.00 - 13.00	Lunch and Exhibition Viewing
14.00	Drug Discovery and Development - Pain and Inflammatory Disease Therapeutic Focus
	14:00 Solace Pharma -Eliot Forster, CEO, New Approaches to Pain
	14.15 Epidyme - Simon McEwen, Director, Desensitisation to Autoimmune Diseases
	14.30 Karus Therapeutics -Simon Kerry, CEO, Karus Therapeutics: new medicines to treat inflammatory disease by modifying gene function

14.45 - 15.45	Diagnostics and Medical Technology Company Showcase (1 further slot available)
	14.45 G-Nostics -Mark Tucker, CEO, Improving the Quality of Care at the Point of Care Through Personalised Treatment
	15.00 Lein Applied DiagnosticsGraeme Clark, Director, Is the eye a window to your health?
	15.15 Oxford BioMaterials Nick Skaer, CEO, Tissue Regenerative Devices: A New Spin on Silk
	15.30 APA Parafricta - George Sampson, CEO, The Preservation of Skin Integrity
	15.45 Biotech-IgG - Alistair Hurst, CEO, Immunotargeting - Pioneering the Possibilities
16.00	Conference Closing Networking Reception and Drinks

17.50 - 18.00 Closing Notes and Conference Close

Overview of the company showcase

Companies were selected on the basis of their fundraising or revenue streams, USP, deal-making, innovation, and IP. The focus is on drug discovery and development, diagnostics and medical technology. The format of the presentations is 15 presentation from each company, including Q&A. Click on each speaker name to read biographies - further speaker biographies will be added as we receive them. Day one features oncology and diabetes therapeutic focus and drug delivery, day two features CNS, pain, and inflammatory disease therapeutic focus, diagnostics and medical technologies.

Selection Process

Please contact our Network Director Jon Rees on 01865 594642 to discuss and apply for a speaking slot. An informed decision will be made based upon information supplied by companies, business intelligence which OBN has gathered through research, potentially with reference to the expert knowledge of members of the OBN Advisory Board and BioTrinity User Groups. Speakers from selected companies must complete a paid registration to benefit from partnering at BioTrinity 2008.

Companies who are not selected to present are encouraged to participate in the one-to-one partnering elements of the meeting for the purposes of business development. .

Criteria for Selection

Consideration will be given to company's USP, or the USP of their leading product, the route-to-market, exit route and milestones.
Consideration is given to revenue streams, demonstrated fund-raising ability, and proximity to market
Efficient use of funding
Recent deal-making success
Innovation in product or business strategy
Preference is given to companies based in the South-East of England
Preference is given to companies which have been trading for less than 7 years
Intellectual property to meet business strategy